Jeremy Graff

Jeremy Graff

Company: HiberCell Inc.

Job title: Chief Development Officer and Senior Vice President of Research


Dr. Graff currently leads the scientific and clinical development for Biothera Pharmaceuticals’ novel innate immune activator, Imprime PGG. Prior to joining Biothera in 2014, Jeremy had led the translational oncology efforts at Eli Lilly and Company. Jeremy’s career has focused on discovering and developing novel agents for cancer therapy.   


Live Q&A 12:20 pm

Read more

day: Online Conference

Imprime PGG- a novel, systemically-delivered, Dectin Receptor Agonist- activates innate immunity, reprogramming the myeloid cells of the tumor microenvironment and driving antigen presentation to enhance the anti-cancer efficacy of the immune checkpoint inhibitor, pembrolizumab 12:00 pm

• Phase 2 clinical data have now shown that Imprime + pembrolizumab provides substantial clinical benefit for patients with metastatic Triple Negative Breast Cancer (mTNBC) • Paired tumor biopsies taken before and on – therapy show robust infiltration of tumor tissue by activated myeloid and T cells • Peripheral blood analyses show monocyte activation as…Read more

day: Online Conference

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.